British Journal of Clinical Pharmacology
Study (n=460) found implementation of an antithrombotic stewardship program (ASP) improved use and safety of antithrombotic medication (ATM), with 54.6% of patients requiring ≥1 intervention from the ASP to optimise care (most commonly to define maximum duration of combined ATMs).
British Medical Journal
Study (n=1057174 matched to 4076342controls, Sweden) suggests covid-19 is risk factor for DVT,PE & bleeding with incidence rate ratios vs. control period significantly increased 70, 110 & 60 days after covid-19, respectively, particularly with more severe covid-19 & comorbidities.
Circulation
RCT (n=229) reports after transcatheter AVR, incidence of leaflet thrombosis was numerically but not statistically significantly lower with edoxaban vs dual antiplatelets (9.8% v 18.4%;p=0.076) & no difference in new cerebral thromboembolism & neurological/neurocognitive function.
The Lancet
RCT (n=753) found asundexian 20 and 50mg daily linked to lower observed rates of bleeding vs. apixaban (ratios of incidence proportions = 0.33;90% CI 0.09–0.97 for 20 & 50mg groups[2 events] v apixaban[6 events]), which was achieved despite near complete in-vivo FXIa inhibition.
The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:
http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services
